Frankfurt - Delayed Quote EUR

MindBio Therapeutics Corp. (WF6.F)

0.0034

+0.0004

+(13.33%)

As of 9:59:02 AM GMT+2. Market Open.

MindBio Announces Sustained Antidepressant Response 3-Months Post Treatment in Microdosing Depression Clinical Trials

Three months post cessation of an 8-week course of microdosing treatment, the antidepressant response is sustained with a 62.8% reduction in depressive symptoms. VANCOUVER, BC / ACCESSWIRE / August 19, 2024 /MindBio Therapeutics Corp. (CSE:MBIO)(Frankfurt:WF6), ...

ACCESS Newswire 9 months ago

MBIO.CN

WF6.F
+13.33%
MindBio Therapeutics Appoints Haywood Securities to Conduct Strategic Investment Advisory

VANCOUVER, BC / ACCESSWIRE / August 1, 2024 /MindBio Therapeutics Corp. (CSE:MBIO)(Frankfurt:WF6), (the "Company" or "MindBio"), a leading biopharmaceutical company in psychiatric medicine development, is pleased to report that it has appointed Haywood ...

ACCESS Newswire 10 months ago

MBIO.CN

WF6.F
+13.33%
MindBio Therapeutics Reports Sustained Antidepressant Response from MB22001 in Depression Clinical Trials

Rapid, robust, and clinically significant reduction in depression symptoms Trials of MB22001 show substantial improvements in mood, energy, creativity, wellbeing, depression and sleep, including REM sleep. One month post cessation of treatment, the ...

ACCESS Newswire 11 months ago

WF6.F
+13.33%

MBIO.CN
MindBio Therapeutics Reports Secondary Data: Improvement of Psychological Outcomes & Safety Results in Depressed Patients from Phase 2A Depression Trial

VANCOUVER, BC / ACCESSWIRE / June 12, 2024 /MindBio Therapeutics Corp. (CSE:MBIO)(Frankfurt:WF6), (the "Company" or "MindBio"), a leading biopharmaceutical company in psychiatric medicine development using microdoses of psychedelic medicines, is delighted ...

ACCESS Newswire 11 months ago

WF6.F
+13.33%

MBIO.CN

Performance Overview

Return	WF6.F	S&P/TSX Composite index (^GSPTSE)
YTD	--	+7.13%
1-Year	-86.72%	+19.51%
3-Year	-96.22%	+30.09%

News

Life

Entertainment

Finance

Sports

New on Yahoo

Yahoo Finance

MindBio Therapeutics Corp. (WF6.F)

MindBio Announces Sustained Antidepressant Response 3-Months Post Treatment in Microdosing Depression Clinical Trials

MindBio Therapeutics Appoints Haywood Securities to Conduct Strategic Investment Advisory

MindBio Therapeutics Reports Sustained Antidepressant Response from MB22001 in Depression Clinical Trials

MindBio Therapeutics Reports Secondary Data: Improvement of Psychological Outcomes & Safety Results in Depressed Patients from Phase 2A Depression Trial

Performance Overview